Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706485 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL10788442 | 0.84 | TTR (0.49) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL12812698 | 0.83 | PPARG (0.50) | SMN1; SMN2AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL7447401 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8383429 | 0.82 | TTR (0.47) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL709158 | 0.82 | POLB (0.50) | SMN1; SMN2AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL6975821 | 0.82 | MAPT (0.52) | SMN1; SMN2AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL5910980 | 0.81 | ALDH3A1 (0.47) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5910982 | 0.81 | ALDH3A1 (0.47) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7508888 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2MEN1KMT2AALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2289890-A1 | Compounds for the treatment of multi-drug resistant bacterial infections | AstraZeneca AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7875715-B2 | 6-[({1-[2-(7-methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; antibacteria; methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant coagulase-negative staphylococci (MRCNS), penicillin-resistant Streptococcus pneumoniae | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | SMN1; SMN2 4251/4885AKR1C3 3541/4885AKR1C2 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.